Zobrazeno 1 - 10
of 17
pro vyhledávání: '"N V, Naoumov"'
Publikováno v:
Journal of Clinical Investigation. 99:3025-3033
Interleukin-12, a cytokine with an important role against intracellular pathogens, promotes Th1 cell development, cellmediated cytotoxicity, and interferon-gamma production. We investigated the immunoregulatory role of IL-12 in 72 chronic hepatitis B
Publikováno v:
Alimentary pharmacologytherapeutics. 27(9)
Individualized treatment regimens, taking into account the heterogeneity of patients with chronic hepatitis C, are needed to improve treatment outcomes.To investigate prospectively the period of undetectable viraemia required for a high rate of susta
Publikováno v:
Casopis lekaru ceskych. 142(10)
The interaction of non-cythopatic, hepatotropic viruses of hepatitis B and C with the host's immune system plays a critical role in determining the viral clearance and it contributes to the liver damage. The initial line of defence is antigen non-spe
Autor:
G, Marinos, S, Rossol, P, Carucci, P Y, Wong, P, Donaldson, M J, Hussain, D, Vergani, B C, Portmann, R, Williams, N V, Naoumov
Publikováno v:
Transplantation. 69(4)
Hepatitis B virus (HBV) recurrence after orthotopic liver transplantation is associated with inflammatory graft changes, despite immunosuppression and donor/recipient HLA mismatch. We investigated whether immune mechanisms are involved in the pathoge
Autor:
H L, Janssen, G, Gerken, V, Carreño, P, Marcellin, N V, Naoumov, A, Craxi, H, Ring-Larsen, G, Kitis, J, van Hattum, R A, de Vries, P P, Michielsen, F J, ten Kate, W C, Hop, R A, Heijtink, P, Honkoop, S W, Schalm
Publikováno v:
Hepatology (Baltimore, Md.). 30(1)
Interferon alfa (IFN-alpha) is the primary treatment for chronic hepatitis B. The standard duration of IFN-alpha therapy is considered 16 weeks; however, the optimal treatment length is still poorly defined. We evaluated the efficacy and acceptabilit
Autor:
F, Torre, N V, Naoumov
Publikováno v:
European journal of clinical investigation. 28(8)
Autor:
G, Marinos, F, Torre, S, Chokshi, M, Hussain, B E, Clarke, D J, Rowlands, A L, Eddleston, N V, Naoumov, R, Williams
Publikováno v:
Hepatology (Baltimore, Md.). 22(4 Pt 1)
The T helper (Th) cell response to hepatitis B core antigen (HBcAg) was analyzed in 76 chronic hepatitis B virus (HBV) carriers with varying degrees of hepatic inflammation and HBV replication. Fifty-five patients had active viral replication, 28 wit
Autor:
S D, Ryder, J, Koskinas, P M, Rizzi, I G, McFarlane, B C, Portmann, N V, Naoumov, R, Williams
Publikováno v:
Hepatology (Baltimore, Md.). 22(3)
The risk of hepatocellular carcinoma in autoimmune hepatitis is low, even in patients with long-standing cirrhosis. Because of the increasing recognition of an association of hepatitis C virus (HCV) with autoimmune hepatitis, at least in some geograp
Publikováno v:
The American journal of gastroenterology. 90(1)
The outcome after liver transplantation for HBsAg-positive liver disease complicated by hepatocellular carcinoma is not clearly defined, and in the present study we analyzed the clinical course in 39 patients transplanted for hepatitis B virus (HBV)-
Publikováno v:
Hepatology (Baltimore, Md.). 19(2)
Serum IgM anti-HBc was determined in 135 chronic HBsAg carriers with various categories of histological activity on liver biopsy and hepatitis B serological profile. Thirty-three patients were treated with interferon-alpha to investigate the correlat